All In Biotech

Drug Trial Radar · NCT07478991

Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

A Randomized Phase III, Global, Multicentre, Open Label Clinical Trial Comparing Venetoclax Azacytidine and Quizartinib Versus Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia Patients Unelegible for Standard Induction Chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

Jul 2, 2026

Primary completion

Apr 2030

Study completion Apr 2030

Sponsor

Lead sponsor
PETHEMA FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Venetoclax+Azacytidine+Quizartinib works better than standard therapy (Venetoclax+Azacytdine) to treat naïve adult patients with acute myeloid leukemia (AML) who are not suitable for standard induction therapy due to age, co-morbidities or other risk factors. The main question it aims to answer is: \- Does the combination of Venetoclax+Azacytidine+Quizartinib show more probability of overall survival than Venetoclax+Azacytdine? Researchers will compare Venetoclax+Azacytidine+Quizartinib to Venetoclax+Azacytdine to see if Venetoclax+Azacytidine+Quizartinib works better than Venetoclax+Azacytdine to treat AML. Participants will be randomized to one of the two treatment arms in a 1:1 ratio, both of which will have treatment cycles of 28 days.

Conditions

  • Acute Myeloid Leukemia, Adult

Interventions

  • AzacitidineDrug

    Subcutaneous injection during the first 7 days of each 28-day cycle until disease progression or end of study

  • VenetoclaxDrug

    Oral Venetoclax during the first 7 days of each 28-day cycle until disease progression or end of study

  • QuizartinibDrug

    Oral Quizartinib during days 8 to 21 of each 28-day cycle until disease progression or end of study .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 4 years

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Complejo Hospitalario de Albacete

    Albacete, Spain · Not yet recruiting

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain · Not yet recruiting

  • Hospital Universitario Torrecárdenas

    Almería, Spain · Recruiting

  • Institut Catalá d´Oncología (ICO Badalona)

    Badalona, Spain · Recruiting

  • Hospital Galdakao-Usansolo

    Barakaldo, Spain · Recruiting

  • Hospital Universitario de Basurto

    Barakaldo, Spain · Recruiting

  • Hospital Universitario de Burgos

    Burgos, Spain · Not yet recruiting

  • Complejo Hospitalario de Cáceres

    Cáceres, Spain · Not yet recruiting

  • Hospital Universitario Puerta del Mar

    Cadiz, Spain · Recruiting

  • H. General de Castellón

    Castelló, Spain · Not yet recruiting

  • Complejo Hospitalario Regional Reina Sofía

    Córdoba, Spain · Not yet recruiting

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Spain · Recruiting

  • Hospital Universitario Juan Ramón Jiménez

    Huelva, Spain · Not yet recruiting

  • Complejo Hospitalario de Gran Canaria Dr. Negrin

    Las Palmas de Gran Canaria, Spain · Recruiting

  • Complejo Hospitalario Universitario Insular-Materno Infantil

    Las Palmas de Gran Canaria, Spain · Recruiting

  • Hospital Universitario de Canarias

    Las Palmas de Gran Canaria, Spain · Recruiting

  • Hospital Universitario Lucus Augusti

    Lugo, Spain · Not yet recruiting

  • Fundación Jiménez Díaz

    Madrid, Spain · Not yet recruiting

  • HLA Hospital Universitario Moncloa

    Madrid, Spain · Not yet recruiting

  • Hospital Clínico San Carlos

    Madrid, Spain · Not yet recruiting

  • Hospital Infanta Leonor

    Madrid, Spain · Not yet recruiting

  • Hospital Univeristario Ramón y Cajal

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain · Recruiting

  • HU Quirónsalud Madrid

    Madrid, Spain · Not yet recruiting

  • H.U. Puerta de Hierro Majadahonda

    Majadahonda, Spain · Not yet recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain · Recruiting

  • Althaia, Xarxa Asistencial de Manresa

    Manresa, Spain · Recruiting

  • Hospital Clinico Universitario Virgen de La Arrixaca

    Murcia, Spain · Recruiting

  • Clínica Universitaria de Navarra

    Pamplona, Spain · Not yet recruiting

  • Hospital Virgen Del Puerto

    Plasencia, Spain · Not yet recruiting

  • Hospital Clínico Universitario de Salamanca.

    Salamanca, Spain · Not yet recruiting

  • Complejo Hospitalario Universitario Nuestra Señora de la Candelaria

    Santa Cruz de Tenerife, Spain · Recruiting

  • H. Marqués de Valdecilla

    Santander, Spain · Not yet recruiting

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    Santiago de Compostela, Spain · Recruiting

  • Hospital General de Segovia

    Segovia, Spain · Not yet recruiting

  • Hospital Universitario Virgen de Valme

    Seville, Spain · Not yet recruiting

  • Hospital Universitario Virgen Del Rocío

    Seville, Spain · Not yet recruiting

  • Hospital General Universitario de Toledo

    Toledo, Spain · Recruiting

  • H. Dr. Peset

    Valencia, Spain · Recruiting

  • Hospital Arnau de Vilanova-Valencia

    Valencia, Spain · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.